NCM
ARQT icon

Nearwater Capital Markets’s Arcutis Biotherapeutics ARQT Stock Holding History

Nearwater Capital Markets’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.3M Sell
607,300
-7,700
-1% -$197K 0.34% 62
2025
Q4 		$17.9M Buy
+615,000
New +$15.7M 0.31% 61

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nearwater Capital Markets's ARQT Position: Q1 2026 in Review

Nearwater Capital Markets reduced its Arcutis Biotherapeutics (ARQT) stake by 1.3% in Q1 2026, selling an estimated $197K and leaving 607,300 shares worth $14.3M. The position accounts for 0.34% of the portfolio, ranked #62.

Nearwater Capital Markets first reported a position in ARQT in Q4 2025 and has held it in 2 quarters since. The position peaked at $17.9M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Nearwater Capital Markets held 607,300 shares of Arcutis Biotherapeutics worth $14.3M as of Q1 2026.
  • Nearwater Capital Markets sold 7,700 Arcutis Biotherapeutics shares in Q1 2026, an estimated $197K.
  • Arcutis Biotherapeutics made up 0.34% of Nearwater Capital Markets's portfolio in Q1 2026, its #62 holding.
  • Nearwater Capital Markets first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • Nearwater Capital Markets's Arcutis Biotherapeutics position peaked at $17.9M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Nearwater Capital Markets's 13F filing for Q1 2026, filed 15 May 2026.